title: [The use of roncoleukin for LAK therapy in ovarian cancer].
abstract: Roncoleukin--recombinant IL-2--was studied with a view to application for LAK therapy. Lymph of ductus thoracicus from ovarian cancer patients receiving adjuvant autolymphochemotherapy was used as source of lymphocytes. Immunobiologic activity of lymphocytes was assayed after 30-minutes incubation with roncoleukin and 24- or 48-hours culturing. The investigation established an increase in T-cell proliferation, autocrine stimulation of IL-2 production, growth of NK-cells cytotoxicity, immediate cytotoxic effect on K562 target cells culture and such sensitizing effect as roncoleukin's potential to boost its susceptibility to NK-lysis. LAK-therapy was used as a component of complex treatment of ovarian cancer (8). Our method has a future in dealing with the present pathology.
authors.forename: E Iu
authors.initials: EIu
authors.lastname: Zlatnik
authors.forename: L Iu
authors.initials: LIu
authors.lastname: Golotina
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology / Q000627:therapeutic use*; D020014:K562 Cells / Q000187:drug effects; D015979:Killer Cells, Lymphokine-Activated; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007376:Interleukin-2; D011994:Recombinant Proteins